A lead-optimization stage biopharmaceutical company
We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta's proprietary tools and understanding of the target allow us to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.